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Abstract 
We performed a clinicopathological study to assess the burden of small vessel disease (SVD) 
type of pathological changes in elderly demented subjects, who had clinical evidence of 
autonomic dysfunction, either carotid sinus hypersensitivity or orthostatic hypotension or both or 
had exhibited unexpected repeated falls.  Clinical and neuropathological diagnoses in 112 
demented subjects comprised dementia with Lewy bodies (DLB), Parkinson’s disease with 
dementia (PDD), Alzheimer’s disease (AD), Mixed dementia (mostly AD-DLB) and vascular 
dementia (VaD).  Of these, 12 DLB subjects had no recorded unexpected falls in life and 
therefore no evidence of concomitant autonomic dysfunction.  A further 17 subjects were 
assessed as ageing controls without significant pathology or signs of autonomic dysfunction.  We 
quantified brain vascular pathological changes and determined severities of neurodegenerative 
lesions including α-synuclein pathology.  We found moderate-severe vascular changes and high 
vascular pathology scores (P<0.01) in all neurodegenerative dementias and as expected in VaD 
compared to similar age controls.  Arteriolosclerosis, perivascular spacing and microinfarcts 
were frequent in the basal ganglia and frontal white matter (WM) across all dementias whereas 
small infarcts (<5 mm) were restricted to VaD.  In a sub-set of demented subjects, we found that 
vascular pathology scores were correlated with WM hyperintensity volumes determined by MRI 
in life (P<0.02).  Sclerotic index values were increased by ~50% in both the WM and neocortex 
in all dementias compared to similar age controls.  We found no evidence for increased α-
synuclein deposition in subjects with autonomic dysfunction.  Our findings suggest greater SVD 
pathological changes occur in the elderly diagnosed with neurodegenerative dementias including 
DLB and who acquire autonomic dysfunction.  SVD changes may not necessarily manifest in 
clinically overt symptoms but they likely confound motor or cognitive dysfunction.  We propose 
autonomic dysfunction promotes chronic cerebral hypoperfusion to impact upon ageing-related 
neurodegenerative processes and characterise their end-stage clinical syndromes.  
Keywords 
Alzheimer’s disease, Autonomic Dysfunction, Dementia, Dementia with Lewy Bodies, 
Microvascular Pathology, Mixed Dementia, Parkinson’s Disease with Dementia, Small Vessel 
Disease, Vascular Dementia 
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Abbreviations
AD, Alzheimer’s disease; CSH, carotid sinus hypersensitivity; CSM, carotid sinus massage; 
DLB, dementia with Lewy bodies; H&E, Haematoxylin and Eosin; OH, orthostatic hypotension; 
PD, Parkinson’s disease; PDD, Parkinson’s disease with dementia; SI, sclerotic index; SVD, 
small vessel disease; WM, white matter; WMH, white matter hyperintensity.
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Introduction
Autonomic dysfunction occurs commonly after 50 years of age.  At least 40% of the elderly with 
Dementia with Lewy bodies (DLB), Parkinson’s disease with dementia (PDD), vascular 
dementia (VaD) and Alzheimer disease (AD) will exhibit some form of autonomic dysfunction.  
They will invariably develop carotid sinus hypersensitivity (CSH), orthostatic hypotension (OH) 
or neurocardiovascular instability, associated with hypotension and bradycardia (2, 7, 23).   CSH 
involving an excessive fall in arterial pressure (53) is reported to occur in 35-58% of elderly with 
AD and DLB (24).  OH develops in nearly 50% of Parkinsonians (16, 18, 43, 49, 50) and may be 
present in over 90% of PDD patients (2).  OH is an independent risk for incident dementia (9, 
55) and often accompanied by disabling symptoms, impaired quality of life, dizziness, nausea, 
sweating, and loss of consciousness (1, 4, 32).  
The vascular hypothesis of autonomic dysfunction proposes that recurrent episodic 
hypotension results in chronic cerebral hypoperfusion, especially in the frontal lobe.  This in turn 
causes anoxic damage and leads to impaired cognitive function (45).  While the true burden of 
asymptomatic autonomic dysfunction is unknown (31), it is crucial to protect the ageing brain 
from fluctuations between hyper- and hypotension, which are known to be associated with white 
matter (WM) changes (58).  We previously showed increased WM hyperintensities (WMHs) 
(24) in DLB patients with autonomic dysfunction.  WMHs are also associated with a postural 
drop in blood pressure in PD (39).  Here, we tested the hypothesis that there is increased small 
vessel disease (SVD) or microvascular pathology in patients with clinical evidence of autonomic 
dysfunction or in those with repeated unexplained falls or syncope and progress to dementia.  We 
performed clinicopathological studies to explore the extent of SVD pathological changes (51) in 
patients exhibiting signs of autonomic dysfunction and had developed dementia.  
Materials and Methods
Study design and subjects
This study involved the assessment of a total of 129 subjects.  Demographic, clinical and 
pathological details of all the subjects are given in Tables 1 and 2.  Initially, we screened clinical 
records and post-mortem reports filed between 1992 and 2017.   Of the 350 records screened, we 
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identified 77 demented subjects, who were assessed for autonomic function in the Falls and 
Syncope Service (FASS) at the Royal Victoria Infirmary, Newcastle upon Tyne and had had a 
post-mortem (Table 1).   We then found 23 additional dementia cases with clinical records 
reporting repeated unexplained falls prior to death.  This information was used as a proxy for the 
presence of autonomic dysfunction (1, 2).   In total, we identified 100 demented subjects with 
direct clinical or reported evidence for autonomic dysfunction (Table 2).  The unexplained falls 
in these individuals were deemed to be for reasons other than arthritis, osteoporosis or joint 
disease.  We also identified an additional 12 DLB cases with no reported unexplained falls prior 
to death (Table 2).  This group with likely no or minimal autonomic dysfunction was compared 
with those DLB subjects, who had clear evidence of autonomic dysfunction or repeated 
unexplained falls.  We could not find any cases diagnosed with PDD, AD, VaD or mixed 
dementia and without evidence of autonomic dysfunction and had come to post-mortem.   
Furthermore, we identified 17 similar age controls with no evidence of reported falls, syncope or 
autonomic dysfunction (Table 2).  We could not find any control subjects, who were clinically 
assessed in the FASS for autonomic function or had falls or syncope and had had a post-mortem.   
There were also no dementia cases tested in the FASS without autonomic dysfunction and had 
had an autopsy. 
Patients suspected of autonomic dysfunction with recurrent symptoms of syncope or falls 
had evidence of CSH or OH or both (Table 1).  CSH was diagnosed by an exaggerated 
haemodynamic response to longitudinal carotid sinus massage (CSM).  The exaggerated 
response was defined as >3 seconds of asystole (cardioinhibitory CSH) or a fall in systolic blood 
pressure in excess of 30 mmHg whilst supine or 50 mmHg whilst in the upright position 
(vasodepressor CSH) during 5 seconds of carotid sinus stimulation by longitudinal massage over 
the carotid sinus (24, 28, 29, 37).  OH was defined as >30 mmHg drop in systolic blood pressure 
after an active stand test (Head-up tilt test) (11, 54).  Patients diagnosed with OH had undergone 
CSM and were confirmed not meet the clinical diagnostic criteria for CSH.   The mean interval 
between the time of autonomic function assessment and death was 1.92 years with a range from 
0 to 7 years.  Almost 80% of the subjects died 3 years after they were assessed in the FASS.  The 
neuropsychometric assessments included the revised Cambridge Cognition Examination 
(CAMCOG) battery and Mini-Mental State Examination (MMSE).   Sub-scores for cognitive 
domains including memory, orientation and other domains of executive function were generated 
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from the total scores (3).   The suspected clinical diagnosis of dementia was confirmed at   
monthly clinicopathological consensus meetings where clinicians met with the pathologists to 
designate a final diagnosis in accordance with current criteria including the diagnostic and 
statistical manual of mental disorders, 4th Edition (DSM-IV). 
Study subjects were participants of the Newcastle longitudinal prospective dementia 
series.  They had a clinical diagnosis of either DLB, PDD, mixed dementia (Mixed), AD or VaD.  
VaD subjects were participants of the Newcastle Cognitive Function After Stroke study (3).  
Age-matched control subjects aged >70 years were either part of previous prospective studies or 
based on unrelated brain donations to the Newcastle Brain Tissue Resource (NBTR).  They were 
included as controls if they had not been diagnosed with autonomic dysfunction, cognitive 
impairment or any neurological or psychiatric illness.  Ethics approval was granted by local 
research ethics committees of the Newcastle upon Tyne NHS Foundation Hospitals Trust.  
Permission for use of brains for post-mortem research was also granted by consent from the 
participants themselves or next-of-kin or family member.  Brain tissues were retained in and 
obtained from the NBTR.
Magnetic Resonance Imaging  
A total of 42 subjects who had post-mortem had undergone brain MRI in life.  T2-weighted MRI 
images (T2WI) were obtained in each case, and WMH volumes (vWMHs) estimated using 
previously validated in house software (12). The mean time from MRI scans to death (years + 
SEM) for all the subjects was 6.4 +0.6 years.  For each group this was as follows:  DLB 3.6 +0.7 
years; PDD 4.3 +1.0 years; Mixed 4.6 +0.6 years; AD 8.1 +1.1 years and VaD 6.4 +1.3 years.  
For controls, without autonomic dysfunction it was 12.2 +1.4 years (n=5). The percentage of 
WMH volume per total brain volume (%vWMH/vTB) in disease cases was calculated.  We then 
performed correlation analysis between WMH volume and vascular pathology scores from all 
the demented subjects with autonomic dysfunction (Figure 2).
Brain tissues and Neuropathological analysis
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Neuropathological assessment was carried out as described previously (3).  Briefly, 
haematoxylin and eosin (H&E) staining was used for assessment of structural integrity and 
infarcts, Nissl and Luxol Fast blue staining for cellular patterns and myelin loss, Bielschowsky’s 
silver impregnation and amyloid-β for Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) rating of neuritic plaques, Gallays stain for neuritic pathology, and tau 
immunohistochemistry for Braak staging of neurofibrillary tangles.  Large sections from the 
frontal, temporal (including hippocampal formation), parietal and occipital lobes, caudate-
putamen, brain stem including midbrain, pons and medulla oblongata, and cerebellum were 
examined from sampled regional blocks as identified in the Newcastle brain map (20, 42).   The 
clinical diagnosis of DLB and PDD were confirmed according to established criteria (30).  The 
clinical diagnosis of AD was confirmed on evidence of significant Alzheimer’s-type pathology 
incorporating Braak stages V–VI, moderate-severe CERAD (26) and high ABC scores per 
National Institute of Aging-Alzheimer’s Association guidelines (36), in the general absence of 
significant vascular pathology (Table 2).  The clinical diagnosis of vascular dementia (VaD) was 
made when there were multiple or cystic infarcts, lacunae, border-zone infarcts, microinfarcts 
and small vessel disease, and pathologically confirmed as Braak stage ≤ IV (20, 21).  Mixed AD 
and VaD case was classified when there was sufficient degree of pathology to reach Braak V–VI 
and significant vascular pathology (6).  We also included cases with Mixed dementia, who met 
two or more neuropathological diagnostic criteria for DLB, PDD and AD. 
Vascular pathology scores were derived from the presence of vascular lesions/pathologies 
in brain areas, including the frontal lobe at the level of the olfactory bulbs, temporal lobe at level 
of the anterior hippocampus, and basal ganglia at level of mamillary body. Lesions including 
arteriolosclerosis, cerebral amyloid angiopathy (CAA), perivascular haemosiderin deposition, 
perivascular space dilatation in the deep and juxtacortical WM, myelin loss, and cortical micro 
(<0.5 mm), small (<5 mm) and large (>0.5 cm) infarcts were recorded with increasing severity 
resulting in greater scores (10).  These measures were compatible with the recently established 
vascular cognitive impairment neuropathology consortium criteria (46).  The vascular pathology 
scores were determined as detailed previously (10) with >95% agreement between scoring 
performed by VD and RNK.  CAA was scored using the system described previously (25).   
Tissues from control subjects had occasional ageing-related pathology and were classified as ‘no 
pathological diagnosis’ (Table 2).  Except for neuropathological examination (TP, RHP, PI and 
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RNK), all subsequent morphological analyses were always undertaken under operator blinded 
conditions.  Samples were identified with coded sequential numbers.  In addition, at least two of 
both positive and negative controls were included to monitor the quality of staining.
Assessment of vascular sclerotic index (SI)
H&E stained coronal frontal lobe (Brodmann area 9) sections were analysed to assess SI in a 
total of ~4,000 brain vessels, essentially as described previously (8, 56).  Twenty images from 
each entire depth of the cerebral cortex and the deep WM were randomly captured using a bright 
field microscope (Leitz DIALUX 20, Leica) with a 10x objective lens coupled to a lumenera 
infinity digital camera (Lumenera Corporation, Canada).  Using VasCalc software (56), internal 
diameter and external diameter of each vessel was measured in three opposing axis.  Sclerotic 
index (SI) was calculated using the following formula: SI = (External diameter - Internal 
diameter) / (External diameter).  Three SI values were calculated from three measured axis in 
each vessel and averaged.   The inter-rater reliability between the assessors was 0.9 either DV 
and RK (SVD pathology scores) or YH and RK (SI scores).
Statistical analysis
Statistical analysis was carried out using SPSS (IBM, version 23.0, IBM Corporation, Armonk, 
NY, USA) with the level of significance set at P<0.05. First, distribution of values was tested 
using the Shapiro-Wilk test followed by one-way analysis of variance (one-way ANOVA) with 
post-hoc Tukey’s tests for normally distributed values or Kruskall-Wallis H tests for non-
normally distributed values to compare data amongst autonomic dysfunction plus dementia and 
control group. Student’s t-test or Mann-Whitney U test was used for normally or non-normally 
distributed data respectively to assess the differences between cortex and WM data.  Spearman’s 
rho correlation was used to assess the relationship between WM hyperintensity volumes and 
vascular pathology.  Pearson’s correlation was used to assess the correlation between vascular 
pathology and microinfarcts/microbleeds. Anonymized data will be shared by request from any 
qualified investigator.  All the data we have generated in this study have been included in this 
paper.
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Results
Clinical features in the autonomic dysfunction plus dementia subjects
Tables 1 and 2 provide the mean age and gender distributions of all the dementia subjects with 
relevant clinical manifestations.  We noted that the mean age of PDD subjects was marginally 
lower compared to controls and other autonomic dysfunction plus dementia subjects (†P<0.01) 
(Table 1 and 2).  Of the 77 dementia subjects tested in the FASS, 29 (38%) had evidence of both 
OH and CSH (Table 1).  The total CAMCOG and MMSE scores indicated all subjects had 
evidence of dementia at least 6 months prior to death.  There were no differences in CAMCOG 
memory and executive sub-scores amongst the autonomic dysfunction plus dementia groups 
(Table 1).  We further noted that on average 55% of the autonomic dysfunction plus dementia 
subjects exhibited hypertension and often had more than one other vascular disease risk factor 
including diabetes mellitus (DM), ischaemic heart disease (IHD) and smoking (Table 1). The 
frequency of hypertension in DLB without falls subjects was 33%, which was not different 
compared with that in dementia subjects who had autonomic dysfunction (Chi-square test). 
Cerebrovascular Pathological changes in Dementia with Autonomic Dysfunction
Table 2 provides details of clinically tested autonomic dysfunction subjects and ageing controls 
assessed for SVD or microvascular pathology.  None of the control subjects had reported 
unexplained falls in life or had been tested in the FASS.  Subjects with dementia exhibited the 
expected pathology defining each type of disease.  The Mixed and AD subjects had the highest 
amount of neurofibrillary tangle (Braak stage) and neuritic or amyloid β plaque burden (Table 2).  
The DLB, PDD and VaD groups had relatively lower burdens of AD-related hallmark 
pathologies and there was even less in ageing controls (*P<0.01; **P<0.01) (Table 2).   In 
addition, nigral Lewy body pathology and neuronal loss were characteristically most severe in 
DLB, PDD and Mixed dementia subjects (Table 2).  Of the 13 VaD subjects clinically diagnosed 
with autonomic dysfunction, 3 had some degree of Lewy body pathology (Table 2).   
VaD subjects expectedly exhibited the highest vascular and WM pathology scores (10).   
However, remarkably all neurodegenerative dementia groups including DLB, PDD, Mixed and 
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AD had high vascular pathology scores compared to ageing controls (‡P<0.01) (Table 2).  AD 
subjects had the highest ABC scores (36) and the greatest frequency of moderate to severe CAA 
(Table 2).  The types of vascular changes seen in subcortical regions in the autonomic 
dysfunction plus dementia subjects predominantly constituted those akin to SVD or 
microangiopathy, which included arteriolosclerosis, intimal thickening, fibroid necrosis, 
hyalinisation, perivascular spacing,  microinfarcts, WM rarefaction and cerebral amyloid 
angiopathy (10) (Figure 1A, a-f).  WM scores incorporating demyelination (17) were also greater 
in the dementia cases compared to controls.  Variable calcification was present in numerous 
vessels within the extrapyramidal regions particularly in and vicinity of the globus pallidus 
(Figure 1B, a-d) that we also observed, albeit to a lesser degree in normal ageing controls.  The 
diameters of the calcified vessels ranged 40 to 160 μm.  However, distribution of the vascular 
pathology scores in different brain regions indicated that higher scores were evident in the frontal 
lobe and the basal ganglia (Figure 1C).  There was high predilection for microinfarcts in the 
frontal lobe WM as well as the basal ganglia across all the dementias.  
Further verification of our observations on clinically tested subjects was evident from 
retrospective assessment of DLB subjects, who had had no apparent autonomic dysfunction 
(Table 2) and of demented subjects who had had repeated unexplained falls in life (Table 2).  
The vascular pathology features and scores in most of the dementia subjects were similar or 
higher compared to those who were clinically tested in the FASS (Table 2).  We also could not 
find differences in SVD features in demented individuals whether they were clinically tested in 
the FASS or experienced unexplained falls as proxy for autonomic dysfunction.  However, the 
key observation was that DLB subjects without reported unexplained falls or autonomic 
dysfunction, had lower vascular pathology scores compared to dementia subjects who had 
autonomic dysfunction.  The vascular pathology scores in DLB subjects without autonomic 
dysfunction were also not different from ageing controls (P=0.236) (Figure 1C).   We also found 
a positive correlation between severity of CAA and haemosiderin deposition (proxy for 
microbleeds) (r=0.88, P=0.01) but not between CAA and microinfarcts (P>0.05).  We further 
noted that the degree of arteriolosclerosis was strongly correlated with numbers of microinfarcts 
(r=0.87, P=0.012) (Table 2).
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Correlation between Vascular pathological changes and WMH volumes upon MRI
To strengthen the evidence that WMHs associated with the various dementias in life (Figure 2A) 
reflected greater SVD or microvascular pathology, we tested the relationship between vWMHs 
determined by T2WI MRI and vascular pathology scores evaluated after post-mortem in those 
subjects who exhibited autonomic dysfunction.  We found there was a positive correlation (ρ= 
0.40, P=0.016) between vWMH and vascular pathology scores across the dementias (Figure 2B).   
However, there was no clear relationship between vWMH and any of the other 
neurodegenerative disease markers such as tau or α-synuclein pathology (P>0.05).    
Sclerotic Index and autonomic dysfunction plus dementia
We then quantified the degree of arteriolosclerosis using the SI (Figure 3A) in the deep WM and 
entire depth of the cortex of the frontal lobe.  The SI was consistently higher by 40-50% in all of 
the autonomic dysfunction plus dementia subjects compared to controls in both the frontal cortex 
and the WM (**P<0.01 and ††P<0.01 respectively) (Figure 3B).  Dementia subjects exhibited 
higher SI values in the cortex compared to the WM, particularly in AD subjects (¶P<0.05), 
whereas controls showed similar SI values in both the cortex and WM (Figure 3B).  However, it 
was notable that DLB subjects without falls exhibited similar SI values as ageing controls and 
lower SI values, particularly in the WM compared to all dementia with evidence of autonomic 
dysfunction (‡P<0.035) (Figure 3B).
Discussion
We previously reported that deep WMHs correlated with autonomic dysfunction in DLB subjects 
(24).  In this study, we provide robust evidence for the presence of significantly greater degree of 
SVD pathology including WM changes in dementia subjects with clinical evidence of 
concomitant autonomic dysfunction.  The remarkable finding is that irrespective of common 
dementia type whether DLB, PDD, Mixed dementia, AD or VaD they all exhibited greater SVD 
type of pathological changes in the presence of autonomic dysfunction.  This was corroborated 
by low vascular pathology scores and SI values in DLB subjects without evidence of autonomic 
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dysfunction. Whereas the highest burden of SVD pathology (51) consisting of microinfarcts, 
lacunar infarcts, severe arteriolosclerosis, WM rarefaction and perivascular spacing was present 
in VaD, it was rather surprising that subjects diagnosed with neurodegenerative dementias 
including PDD, DLB and AD exhibited these similar microvascular changes particularly severe 
arteriolosclerosis and perivascular spacing.   SI values were higher by 45-50% signifying 
moderate-severe arteriolosclerosis in dementia cases with autonomic dysfunction.  
Arteriolosclerosis and microinfarcts are strongly associated with cognitive impairment (5, 19, 
52), and were consistent features across all dementias.  Vascular pathology scores, particularly in 
the WM were also increased and correlated with vWMHs in those demented subjects with 
autonomic dysfunction.   These observations collectively suggest arterial wall changes and 
thickening may impact on blood rheology to impair cerebral blood flow and perfusion (20). 
With reference to other features of SVD such as CAA, except in AD, dementia subjects 
with and without autonomic dysfunction exhibited similar CAA pathology to ageing controls.  
This further suggested that CAA was not necessarily a factor in the observed arteriosclerotic 
differences in demented subjects with and without autonomic dysfunction.  While, we observed 
strong correlations between arteriolosclerosis and microinfarcts and between CAA and 
haemosiderin deposition or microbleeds, we did not observe correlations between CAA and 
microinfarcts (40, 47).  The latter is probably because we had low numbers of cases in the 
analysis and had included VaD subjects, who showed relatively low CAA but high burden of 
microinfarction.   The frequency of hypertension in ‘DLB without falls’ group was not different 
from other dementia groups.  Moreover, DLB subjects without falls exhibited similar SI values 
as ageing controls but had lower SI values, particularly in the WM, compared to all dementias 
with concomitant of autonomic dysfunction.  This suggests hypertension per se was not 
necessarily a factor in the observed differences in SVD pathology in demented subjects with and 
without autonomic dysfunction.
             Large vessel disease may also contribute to SVD type of changes in the WM and to 
microinfarcts (20, 51, 57).  In comparison to the neurodgenerative dementias, VaD subjects bear 
greater degrees of large vessel disease i.e. intracranial and extracranial atherosclerotic disease.  
In a recent study (14), we noted that regardless of severity of carotid artery stenosis, most of the 
infarcts were small (<5mm in size) and most were located in the cerebral cortex.  In a previous it 
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was further noted that cerebral atherosclerosis was not only expectedly associated with cystic 
infarcts but importantly microinfarcts (57).  It would appear microinfarcts arise from a 
combination of mechanisms including artery-to-artery embolism, cardiogenic embolism and 
haemodynamic impairment that likely involve microemboli.
In comparison to ageing controls with no recorded autonomic dysfunction and DLB 
subjects without reported falls, overall our findings indicate SVD pathological changes are 
common in elderly subjects with autonomic dysfunction irrespective of the type of dementia they 
acquire.  This may compound effects of co-existing pathologies including neurofibrillary or α-
synuclein pathology or amyloid deposits, which albeit may occur even in cases of pure 
autonomic failure such as idiopathic OH or Bradbury-Eggleston syndrome (pure autonomic 
failure causing idiopathic OH) (ROC and RNK, unpublished observations).  It seems reasonable 
to conclude that cerebral SVD changes contribute to the clinical syndrome in elderly subjects 
who develop dementia and exhibit autonomic dysfunction.  While these ageing-related SVD 
changes may not result in overt neurological signs or cerebrovascular events except in VaD, they 
likely collectively contribute to the declining brain health of the elderly with autonomic 
dysfunction.   
Our findings underscore that vascular protection is important in patients who develop any 
type of dementia and are symptomatic or even asymptomatic for autonomic dysfunction.  We 
enrolled symptomatic autonomic dysfunction plus obviously demented subjects.  However, some 
patients with neurodegenerative diseases and dementia develop autonomic dysfunction prior to 
motor and cognitive symptoms.  A previous study reported that up to 40% of PD patients with 
autonomic dysfunction were ‘asymptomatic’, and even ‘asymptomatic’ autonomic dysfunction 
caused higher prevalence of falls, worsened activities of daily life (ADL) and affected their 
quality of life (QOL) (31).  In a follow up study (32), the severity of autonomic symptoms 
progressed by 20% over the course of a year and was independently associated with impairment 
in ADLs and QOL.  Symptomatic and asymptomatic OH were both associated with increased 
falls and health care utilization.  Thus, ‘asymptomatic’ autonomic dysfunction has almost similar 
detrimental effects to being symptomatic.  Importantly, if ‘asymptomatic’ autonomic dysfunction 
could be established clinically at early stages of cognitive impairment, relevant treatment or 
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intervention(s) has the potential to prevent further cognitive decline in patients with 
neurodegenerative dementias.
While our study provides good evidence to support our hypothesis in that autonomic 
dysfunction is linked to alterations in the cerebral vasculature of subjects with neurodegenerative 
diseases, it is unclear whether autonomic dysregulation is a consequence or an instigator of 
dementia.  A recent study (38), provided novel evidence for autonomic dysfunction in mild 
cognitive impairment.  This was associated with orthostatic blood pressure dysregulation and 
suggests that dysautonomia is an early feature in the development of cognitive dysfunction.   
CSH is an important risk factor for hypertension, IHD and systemic atherosclerosis (48).  In our 
cohort, autonomic dysfunction plus dementia subjects displayed frequent vascular risk factors.  
These may contribute to atherosclerosis in the carotid arteries, affecting the baroreceptors (27) 
and possibly intracranial cerebral arteries to cause deep WM changes (15, 24) and worsen 
cognitive function.  Alternatively, CSH may independently cause chronic or episodic 
hypotension promoting abnormal perfusion with resultant changes in cerebral small vessels and 
the WM leading to cognitive decline.  While previous studies have confirmed the association 
between features of autonomic dysfunction e.g. OH and selective cognitive deficits, albeit in PD, 
they have rejected the hypothesis that this is underlined by the development of cerebrovascular 
disease (43).  The underlying mechanism could be mediated by development of cerebrovascular 
disease induced by chronic or episodic hypoperfusion but until now the extent of brain vascular 
load in PD or DLB patients with OH was not elucidated.
Another hypothesis is that generalised brain α-synuclein pathology or focal α-
synucleinopathy in the sympathetic ganglia relates to autonomic dysfunction and dementia.   
Clinical and post-mortem neuropathological findings in patients with PD and DLB, both 
clinically diagnosed as pure autonomic failure (PAF) revealed that neurodegeneration in PD and 
DLB may originate from outside the CNS in autonomic postganglionic neurons (22).  
Involvement of postganglionic sympathetic nerves including the cardiac sympathetic nerves were 
predominant in PD and PAF (41), suggesting that the cardiac but not the medullary sympathetic 
neurones are affected in people with PD and PAF.  Cardioinhibitory CSH in patients with Lewy 
body pathology was also related to severity of the cardiac sympathetic neurons rather than in 
CNS (44).  Furthermore, severity of autonomic dysfunction was associated with cognitive 
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dysfunction in patients with PD (50).  These reports strongly support our findings in that PDD 
and DLB, which exhibit extensive brain Lewy body pathology, showed similar SVD pathologies 
and cognitive dysfunction as those cases with autonomic dysfunction plus dementia without 
significant Lewy body pathology.  Thus, extensive Lewy body pathologies in the brain may not 
directly affect SVD pathological changes to lead to dementia but autonomic dysfunction related 
cerebral hypoperfusion likely contributes to microvascular pathology, WM changes and 
cognitive decline in patients with Lewy body pathology.  It is plausible, however, that the 
observed SVD pathological changes result from neuronal damage in the brainstem nuclei or 
disruption of the mon aminergic neuronal system (27, 35).  While further investigation is 
necessary, we observed alpha-synuclein pathology in sympathetic ganglia of some VaD subjects, 
suggesting autonomic dysfunction in VaD could partly result from alpha-synuclein pathology in 
the sympathetic nervous system.
We emphasise that one of the main limitations of our study is that we were not able to 
find and compare groups of dementia subjects who were tested in the FASS, did not have 
evidence of autonomic dysfunction and had come to post-mortem.  As suggested by several 
clinical studies (cited above), high numbers of dementia patients may be ‘asymptomatic’ for 
autonomic dysfunction and it is likely that they bear considerable burden of SVD pathology.  We 
previously demonstrated the spectrum of vascular pathology in different dementias including 
VaD, AD and DLB (10).   In that previous post-mortem cohort, while we were not aware 
whether any of the patients had autonomic dysfunction or were asymptomatic for it, on the whole 
they tended to exhibit relatively low SVD pathology scores.  Another limitation is that we did 
not quantify microvascular pathology in all the regions of the brain used to score vascular 
pathology.  Such analysis is profoundly cumbersome but in accord with our previous hypothesis 
(13), we concentrated on the deep WM of the frontal lobe and incorporating the centrum 
semiovale.  Finally, in terms of elucidating some mechanistic approaches we did not have 
enough frozen tissues from cases without clear evidence of autonomic dysfunction  to 
substantiate study power and enable biochemical assays of myelin degrading proteins or 
gliovascular unit markers to demonstrate consequences of microvascular damage (13, 17).  
Autonomic functions are regulated in the brainstem, e.g. medulla and its nuclei (34).  In 
patients with CSH, tau pathology was evident in the medullary baroreflex nuclei (35) and 
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medullary vessels were degenerated in patients with multiple system atrophy (MSA) (33).  
Microvascular changes in the brainstem also relate to or are caused by autonomic dysfunction.  A 
future expanded analysis of SVD pathological changes involving other brain regions, particularly 
in the brainstem in this cohort may provide more evidence to elucidate the pathophysiological 
mechanisms and impact of autonomic dysfunction on microvascular changes in dementia 
patients.  
Conclusions
In summary, autonomic dysfunction irrespective of final diagnosis of dementia type is associated 
with consistent higher burden of SVD pathological changes, particularly in the deep WM.  These 
SVD changes do not necessarily manifest into overt clinical signs but likely add to the dementia 
syndrome.  Our findings implicate that autonomic dysfunction is an important risk factor of 
chronic cerebral hypoperfusion, which may differentially affect neurodegenerative processes to 
produce the end-stage pathology.  We propose the importance of assessing autonomic 
dysfunction in patients with dementia, particularly at an early stage.  Treatment for detrimental 
autonomic dysfunction (even when it is asymptomatic) implementing stricter control of vascular 
risk factors, pacemakers, life-style intervention or pharmacological approaches might be 
effective therapeutic strategies to reduce SVD during ageing and prevent or slow down cognitive 
decline in patients with autonomic dysfunction plus dementia, in addition to reducing their 
immediate risk of falls.
.
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Table 1:  Clinical features in the autonomic dysfunction plus dementia subjects assessed in the FASS
All dementia subjects had clinical evidence of autonomic dysfunction.  All dementias group represent all causes of dementia including 
DLB, PDD, Mixed, AD and VaD; Mixed dementia: 7 =AD+DLB, 6 =AD+VaD, 3=AD+DLB+VaD and 1= PD+DLB+VaD.
Age, †P<0.01 vs Control, DLB, Mixed, AD and VaD; ‡P<0.01 vs AD and VaD; P=0.057, Mixed vs AD; P=0.053, Mixed vs VaD; 
OH, orthostatic hypotension; CSH, carotid sinus hypersensitivity; ‘OH / CSH / OH and CSH, number’ indicates number of cases who 
had OH / CSH / both OH and CSH in each group. For example, in DLB group, OH / CSH / OH and CSH are described as 12, 10, 7. 
          Variable All dementias DLB PDD Mixed AD VaD
Number of subjects 77 16 13 17 18 13
Age, years, mean (range) 82.3 (64-98) 79.6 (69-96)‡ 72.8 (64-81)† 83.0 (72-93) 87.8 (76-96) 88.1 (75-98)
OH / CSH / OH and CSH, 
number
58, 42, 29 12, 10, 7 11, 5, 3 12, 11, 8 14, 11, 9 9, 5, 2
Total CAMCOG score 
(/100), mean (range)
54.2 (20-80) 53.8 (24-80) 61.1 (39-74) 51.0 (23-68)* 44.0 (20-73) 61.2 (25-80)
Memory sub-score (/27),
mean (range)
13.7 (4-23) 14.9 (8-21) 16.2 (9-23) 13.5 (4-23) 10.0 (5-14) 14.1 (4-22)
Executive sub-score (/28), 
mean (range)
11.2 (2-19) 12.1 (4-23) 9.6 (5-18) 11.2 (7-15) 12.3 (10-17) 10.6 (2-19)
MMSE score (/30), 
mean (range)
13.1 (0-24) 13.8 (6-20) 14.2 (3-20) 11.9 (2-19) 8.5 (0-16) 17.2 (8-24)¶
Hypertension, number (%) 42 (55%) 11 (69%) 7 (54%) 7 (41%) 9 (50%) 9 (69%)
Systolic BP, mean (range) 146 (101-200) 149 (122-187) 152 (101-200) 142 (109-186) 141 (110-165) 146 (131-172)
Diastolic BP, mean (range) 76 (51-120) 74 (60-86) 82 (57-120) 74 (53-98) 72 (51-95) 76 (52-92)
Other VRF, number
(smoking / DM / IHD)
32/5/15 7/0/4 6/1/3 6/1/3 5/3/2 8/0/3
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This means 12 cases in DLB had OH, 10 subjects confirmed to have CSH and 7 had evidence to have both OH and CSH (OH and 
CSH overlapped in some cases); Total CAMCOG score, *P=0.034 vs PDD, *P=0.028 vs VaD; CAMCOG executive and memory 
subscore, n.s. between groups; MMSE score, ¶P=0.041 vs DLB, ¶P=0.021 vs Mixed, ¶P=0.003 vs AD; Hypertension, number (%),  
n.s. between groups (Chi-square test);  Systolic and Diastolic BP, n.s. between groups. Clinical features other than age and gender in 
Controls and DLB without falls cases were not completely available as they were not assessed at the falls and syncope clinic (FASS).
Abbreviations:  AD, Alzheimer’s disease; BP, blood pressure; CAMCOG, revised Cambridge Cognition Examination; DLB, 
Dementia with Lewy Bodies; DM, diabetes mellitus; F, female; IHD, ischaemic heart disease; M, male; Mixed, Mixed dementia; 
MMSE, Mini-Mental State Examination; PDD, Parkinson’s disease with dementia; VaD, Vascular dementia; VRF, vascular risk 
factor; WML, white matter lesion. 
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Table 2
Neuropathological features of all dementia cases and similar age controls in the study
          Variable Controls
DLB 
without 
Falls
All 
dementias DLB PDD Mixed
ǂ AD VaD
Number of subjects 17 12 100 24 18 22 18 18
Age, years, mean (range) 86.9 (72-99)
80.0 
(74-90)&
82.0 
(64-98)
79.6 
(69-96)‡
74.6 
(64-89)†
83.4 
(72-93)
87.8 
(76-96)
85.8 
(71-98)
Gender, number (F/M) 13 / 4 1 / 11 52 / 48 11 / 13 9 / 9 16 / 6 9 / 9 7 / 11
Autonomic Dysfunction 
(n=)§ 0 0 100 24 18 22 18 18
Braak Stage, mean 
(range) 1.9 (0-4) 3.0 (0-6) 3.3 (0-6) 2.2 (0-4) 2.0 (0-4) 4.8 (2-6)* 5.6 (5-6)** 1.6 (0-4)
CERAD, mean (range) 0.5 (0-2) 1.2 (0-2) 1.7 (0-3) 1.5 (0-3)ϕ 0.5 (0-2) 2.6 (0-3)* 2.9 (2-3)** 0.8 (0-3)
Alzheimer’s Disease 
Neuropathologic 
Changes; A, B, C 
(mean)♯
A0.5, 
B1.2, C0.5
A1.2, 
B1.6, C1.2
A1.5, 
B1.8, C1.7
A0.9, 
B1.3, C1.5
A0.4, 
B1.1, C0.5
A2.5, 
B2.6, C2.6
A3, 
B3, C3
A0.6, 
B1.2, C0.8
Vascular pathology 
score, 
mean (range)♯
6.7 
(0-10)‡
8.1 
(5-10)&
11.4 
(5-18)
9.9 
(5-13)
10.8 
(7-17)
11.9 
(7-15)
11.2 
(6-16)
13.6 
(10-18)¶
White matter lesion 
score,
mean (range)
0.5 (0-2)§ 1.6 (1-3) 2.2 (0-3) 2.0 (1-3) 2.1 (1-3) 2.1 (0-3) 1.8 (0-3) 2.9 (2-3)ψ
White matter/Vascular 
lesions, moderate - 
severe (%)
17.6** 41.7* 94 83 94 91 72 100
Lewy body pathology, 
number 
0 / 0 2 / 7 16 / 36 3 / 19 5 / 10 5 / 7 0 / 1 3 / 0
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(limbic/neocortical)
SN neuronal loss (n=),
(none/mild/moderate/
severe)
N/A 3/1/3/5 19/25/28/24 0/4/11/8 0/1/4/12 3/5/9/4 7/8/2/0 9/7/2/0
CAA, total (%) 17.6 8.3 18.6 8.3 5.6 18.2 66.7** 27.8
CAA, moderate-severe 
(%) 5.8 8.3 10.1 0.0 5.6 9.1 38.9** 16.7
Arteriolosclerosis, 
moderate-severe (%) 5.9** 25.0 60.6 45.9 61.1 63.4 61.1 66.7
Microinfarct, total (%) 35.3** 25.0** 81.1 79.1 88.9 77.3 66.7 100*
Microinfarct, moderate-
severe (%) 0.0* 0.0* 30.5 25.0 33.3 27.2 15.6 76.9**
Haemosiderin deposition 
(microbleeds), total (%) 0.0 0.0 15.0 8.3 11.1 9.1 33.3** 16.7
Brain only necropsy (%) 100 25 72.0 70.8 88.9 95.4 66.7 33.3
Intracranial MCA 
stenosis, moderate-severe 
(%)
N/A 16.7 14.0 4.2 5.6 0.0 11.1 90.9
Extracranial ICA 
stenosis, moderate-severe 
(%)
N/A 0.0 16.8 N/A 0.0 N/A 11.1 100
α-Synuclein pathology in 
the sympathetic ganglia, 
moderate-severe (n=)
N/A N/A 5 N/A 1 N/A N/A 4
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§All dementia subjects had clinical symptoms or evidence of autonomic dysfunction.  ǂMixed dementia group represents: 7=AD+DLB, 
7=AD+VaD, 4=AD+DLB+VaD, 3=DLB+VaD and 1=PD+DLB+VaD. 
Age, †P<0.01 vs Control, DLB, Mixed, AD and VaD;  ‡P<0.01 vs AD and VaD; &P<0.01 vs AD and VaD; Braak Stage, **P<0.01 vs 
Control, DLB without Falls, DLB, PDD and VaD; **P<0.05 vs Mixed; *P<0.01 vs Control, DLB and PDD; *P<0.01 vs DLB without 
Falls and VaD; CERAD, **P<0.01 vs Control, DLB, PDD and VaD; *P<0.01 vs Control, DLB, PDD and VaD; ϕP<0.05 vs Control;  
ϕP<0.01 vs PDD; ♯Alzheimer’s Disease Neuropathologic Changes (36); ♯Vascular Pathology Score (10), ‡P<0.01 vs DLB, PDD, 
Mixed, AD and VaD; &P<0.01 vs PDD, Mixed, AD and VaD; ¶P<0.05 vs DLB without Falls, DLB and PDD; White matter lesion 
score, §P<0.01 vs DLB without Falls, DLB, PDD, Mixed, AD and VaD; ψP<0.01 vs DLB without Falls, DLB, PDD, Mixed and AD;  
White matter/Vascular lesions, **P<0.01 vs Control, DLB, PDD, Mixed, AD and VaD; *P<0.05 vs Control, DLB, PDD, Mixed, AD 
and VaD (Chi-square test); Lewy body pathology, only the number of limbic/neocortical cases are shown. Fifteen Controls, 7 Mixed, 
15 AD and 14 VaD cases had no Lewy body pathology.  Two controls, 1 DLB, 2 Mixed and 1 AD showed Lewy body pathology in 
brain stem.  Data were not available for 1 case in DLB and PDD groups due to limited autopsy; Neuronal loss in the substantia nigra, 
data was not available for 1 case in each group other than VaD due to limited autopsy. CAA total (%) and CAA moderate-severe (%), 
**P<0.01 (Chi-square test); Arteriolosclerosis moderate-severe (%), **P<0.01 (Chi-square test); Microinfarct total (%) and CAA 
moderate-severe (%), **P<0.01, *P<0.05 (Chi-square test); Microbleeds total (%), **P<0.01 (Chi-square test).  
Abbreviations:  AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; CERAD, Consortium to Establish a Registry for 
Alzheimer’s Disease; DLB, Dementia with Lewy Bodies; F, female; ICA, internal carotid artery; M, male; Mixed, MCA, middle 
cerebral artery; Mixed dementia; PDD, Parkinson’s disease with dementia; SN, substantia nigra; VaD, Vascular dementia; WML, 
white matter lesion. 
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Figure Legends
Figure 1: Spectrum of SVD pathology (subcortical cerebrovascular lesions) in autonomic 
dysfunction plus dementia subjects.  A (a-f), Representative images (H&E staining) of 
different vascular pathologies in frontal WM (a-d) and basal ganglia (e and f) observed in 
autonomic dysfunction plus DLB and PDD subjects.  A (a), vascular wall thickening with 
perivascular spacing; A (b), perivascular spacing; A (c), small infarct (arrows); A (d), 
perivascular microinfarct; A (e), microvascular hyalinosis with perivascular spacing; A (f), 
rarefaction (arrows).  B (a-d), Representative images (H&E stain) of microvascular changes and 
variable calcification bserved in DLB and PDD subjects.  B (a-d), microvascular hyalinosis; B 
(b, c and d), calcification in the vessel wall.  C, Bar chart showing the total vascular pathology 
scores and distribution of individual vascular pathology scores in different regions of the brain.  
All dementias with autonomic dysfunction groups showed consistently higher total (¶P<0.008) 
and individual vascular pathology scores compared to controls, particularly in both the frontal 
lobe and the basal ganglia (**P<0.016 and ††P<0.000 respectively).  In the temporal lobe, DLB, 
Mixed, AD and VaD subjects showed higher vascular pathology scores compared to controls 
(‡P<0.019).  Vascular pathology scores in the hippocampus remained same across all dementias 
and control subjects.  High scores were evident in VaD subjects who also exhibited lacunar 
infarcts.  Subjects with dementia also exhibited microinfarcts particularly in the frontal WM and 
basal ganglia with scores of 5/6 and 3/4 respectively (10). Total and individual vascular 
pathology scores were not different between controls and DLB without Falls.  Scale bar 
represents 100 µm (A, a-f) and 20 µm (B, a-d).
Figure 2: Relationship between WM hyperintensity volumes and vascular pathology in 
autonomic dysfunction.  A (a-f), Axial views of T2-weighted brain MRI images at the level of 
basal ganglia and corona radiata to illustrate degrees of vWMHs in different dementias (b-f) in 
comparison to a control subject without autonomic dysfunction (a).  The mean percentage of 
vWMH per total brain volume and vascular pathology scores in the controls (n=5) was 10.4% 
and 8.8 respectively (a).   B, Correlational analysis between percentage of vWMH per total brain 
volume and vascular pathology scores of demented subjects with autonomic dysfunction.  
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Spearman’s rho correlation analysis revealed that vascular pathology score exhibited a positive 
correlation with % vWMH per total brain volume (ρ=0.40, P=0.016).
Figure 3:  Assessment of vascular sclerotic index in brain vessels.  A, Representative profile 
of a mildly hyalinised microvessel indicating the dimensions used to determine the sclerotic 
index (SI).  The dotted lines mark inner diameters of the vessel.  The normal lines indicate 
external diameters. Scale bar represents 50 µm. B, Histogram showing SI values in the WM and 
the cortex in controls and autonomic dysfunction plus dementia groups.  All dementias with 
autonomic dysfunction groups showed consistently higher mean SI values compared to controls 
in both the WM and the cortex (**P<0.005 and ††P<0.005 respectively).  SI values were not 
different between controls and DLB without Falls in both the WM and the cortex. In the WM, 
DLB without Falls showed lower SI values compared with all dementia with autonomic 
dysfunction groups (‡P<0.035). In autonomic dysfunction plus dementia subjects, higher SI was 
evident in the cortex compared with WM, particularly in AD subjects (¶P=0.019).  
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